ETIDIOH - NEW

Abstract Recent investigations have demonstrated a relationship between the persistence of SARS-CoV-2 and post-COVID-19 conditions . Building upon a potential connection between SARS-CoV-2 persistence and early virologic rebound, we examine the association of early virologic rebound with post-acute mortality and hospitalization due to post-acute sequelae among hospitalized patients with COVID-19 in Hong Kong . Our study includes 13,859, 3959, and 4502 patients in the all-patient, nirmatrelvir/ritonavir, and molnupiravir group , respectively. Results show that patients who experienced virologic rebound exhibited a significantly higher risk of post-acute mortality (hazard ratio [HR], 1.52; 95% confidence interval [CI], 1.36–1.70) with a risk difference [RD] of 7.19%, compared with patients without virologic rebound. A similar increase in the risk of post-acute mortality is also observed in nirmatrelvir/ritonavir-treated patients (HR, 1.78; 95% CI, 1.41–2.25; RD, 12.55%) and molnupiravir-...

  Am J Respir Crit Care Med LAUTRETTE A, Cadoret M, Richard JC, Schwebel C, et al Impact of Visitation Restrictions in ICU on Psychological Symptoms in Family Members: Experience of the COVID-19 Pandemic. Am J Respir Crit Care Med. 2025 Jul 23. doi: 10.1164/rccm.202412-2470. PubMed           Abstract available Clin Infect Dis AKANDE ET, Fowotade AA, Odih EE, Oaikhena AO, et al Genomic Surveillance of SARS-CoV-2 in Ibadan, Oyo State, Nigeria. Clin Infect Dis. 2025;80. PubMed           Abstract available STREINU-CERCEL A, Castagna A, Chang SC, Chen YS, et al Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients with COVID-19 (BIRCH): a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study. Clin Infect Dis. 2025 Jul 22:ciaf406. doi: 10.1093. PubMed           Abstract available BOSCOLO-RIZZO P, Spinato G, De Colle R, Maniaci A, et al Five-Year...

ABSTRACT Many difficult-to-understand clinical features characterize COVID-19 and post-acute sequelae of COVID-19 (PASC or long COVID [LC]). These can include blood pressure instability, hyperinflammation, coagulopathies , and neuropsychiatric complaints . The pathogenesis of these features remains unclear. The SARS-CoV-2 Spike protein receptor-binding domain (RBD) binds angiotensin converting enzyme 2 (ACE2) on the surface of host cells to initiate infection. We hypothesized that some people convalescing from COVID-19 may produce anti-RBD antibodies that resemble ACE2 sufficiently to have ACE2-like catalytic activity , that is, they are ACE2-like proteolytic abzymes that may help mediate the pathogenesis of COVID-19 and LC . In previous work, we showed that some people with acute COVID-19 had immunoglobulin-associated ACE2-like proteolytic activity , suggesting that some people with COVID-19 indeed produced ACE2-like abzymes . However, it remained unknown whether ACE2-like abzymes wer...

  Antiviral Res LEBEDIN M, Petrovsky N, Tabynov K, Tabynov K, et al SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody. Antiviral Res. 2025;241:106235. PubMed           Abstract available BMJ ARETOULI E, Malik M, Widmann C, Parker AM, et al Cognitive and mental health outcomes in long covid. BMJ. 2025;390:e081349. PubMed           Abstract available Clin Infect Dis SIZA C, Plucinski M, Lessa FC, Campelo E, et al Antibody Response in Healthcare Workers During the Severe Acute Respiratory Syndrome Coronavirus 2 Gamma Variant Outbreak in Manaus, Brazil. Clin Infect Dis. 2025 Jul 16:ciaf318. doi: 10.1093. PubMed           Abstract available SHOHAM S, Dioverti MV Combination Therapy for Protracted COVID-19: When More is More. Clin Infect Dis. 2025 Jul 16:ciaf384. doi: 10.1093. PubMed    ...

Abstract We sequenced sarbecovirus from Rhinolophus spp. bats in Bandarban District , Bangladesh, in a genomic surveillance campaign during 2022–2023. Sequences shared identity with SARS-CoV-1 Tor2, which caused an outbreak of human illnesses in 2003 . Describing the genetic diversity and zoonotic potential of reservoir pathogens can aid in identifying sources of future spillovers. Source: US Centers for Disease Control and Prevention,  https://wwwnc.cdc.gov/eid/article/31/8/25-0071_article ____

Abstract Several studies have documented reverse zoonotic transmission of SARS-CoV-2, including in farmed mink which are susceptible to human respiratory viruses and are known for serving as a reservoir capable of generating new virus variants in densely populated farms. Here, we present the results of a genomic investigation launched in response to detected human infections with mink-origin SARS-CoV-2 lineages , and show evidence of at least 14 high-confidence introductions of SARS-CoV-2 from humans into farmed mink in Lithuania where sustained transmission in farmed mink lasted up to a year . We estimated the most likely timeframes for these introductions encompassing at least six SARS-CoV-2 lineages , some of which were already extinct in humans , with Bayesian phylogenetic and molecular clock analyses. This study highlights the public health risks posed by fur farms and underscores that passive genomic surveillance systems are ineffective without the active involvement and expertis...

Summary Background Nirmatrelvir–ritonavir is approved for adults with mild-to-moderate COVID-19 who are at risk of severe disease . There are little clinical data to guide the duration of therapy in patients who are immunocompromised. We aimed to compare the approved 5-day regimen of nirmatrelvir–ritonavir with 10-day and 15-day regimens. Methods This placebo-controlled, randomised, double-blind, phase 2 trial enrolled non-hospitalised, immunocompromised individuals aged 12 years or older with symptomatic COVID-19 from 73 sites across nine countries. Participants were randomly assigned (1:1:1) to receive 300 mg nirmatrelvir and 100 mg ritonavir orally twice per day for 5, 10, or 15 days. Randomisation was stratified according to whether participants were considered immunocompromised due to use of corticosteroids or tumour necrosis factor blockers. Investigators, participants, and caregivers were masked to the assigned study group. The primary endpoint was proportion of randomly assigne...

Summary Background Obeldesivir is an oral nucleoside analogue prodrug antiviral that inhibits SARS-CoV-2 replication . We aimed to assess the efficacy, safety, and tolerability of obeldesivir for the treatment of COVID-19 in non-hospitalised individuals at low risk of progression to severe disease. Methods OAKTREE was a phase 3, randomised, double-blind, placebo-controlled trial in 107 centres (including research centres, primary care centres, and hospitals) in Japan and the USA . Low-risk, non-hospitalised adults and adolescents with mild-to-moderate COVID-19 were enrolled within 3 days of symptom onset. Eligible participants were randomly assigned 1:1 using permuted block randomisation (block size of four), stratified by historical completion of a primary COVID-19 vaccination series, to receive either oral obeldesivir 350 mg or matched placebo twice daily for 5 days. The primary efficacy endpoint was time to COVID-19 symptom alleviation by day 29, which was assessed in all randomly a...

  BMJ HOUSE TA Pandemic response: no one is immune to getting things wrong. BMJ. 2025;390:r1415. PubMed          BHATT N Covid-19: Indian health ministry refutes links between sudden cardiac death and vaccination. BMJ. 2025;390:r1426. PubMed          Infect Control Hosp Epidemiol NEARY M, Quan K, Tjoa T, Bittencourt CE, et al Did universal masking during the COVID-19 pandemic reduce MRSA and MSSA acquisition in the NICU? Infect Control Hosp Epidemiol. 2025 Jul 11:1-6. doi: 10.1017/ice.2025.10209. PubMed           Abstract available Int J Infect Dis BERG J, Linden K, Zaigham M, Domellof M, et al The Association between Antenatal SARS-CoV-2 Exposure and Infant Neurodevelopment at Four Months of Age: A Prospective Multicenter Cohort Survey within the COPE Study. Int J Infect Dis. 2025 Jul 3:107973. doi: 10.1016/j.ijid.2025.107973. PubMed        ...

Abstract Although vaccines and treatments have strengthened our ability to combat the COVID-19 pandemic , new variants of SARS-CoV-2 continue to emerge in human populations. Because the evolution of SARS-CoV-2 is driven by mutation , a better understanding of its mutation rate and spectrum could improve our ability to forecast the trajectory of the pandemic . Here, we use circular RNA consensus sequencing (CirSeq) to determine the mutation rate of six SARS-CoV-2 variants and perform a short-term evolution experiment to determine the impact of these mutations on viral fitness. Our analyses indicate that the SARS-CoV-2 genome mutates at a rate of ∼1.5 × 10−6/base per viral passage and that the spectrum is dominated by C → U transitions. Moreover, we find that the mutation rate is significantly reduced in regions that form base-pairing interactions and that mutations that affect these secondary structures are especially harmful to viral fitness. In this work, we show that the biased mutat...

Highlights •  This study evaluated differences in SARS-CoV-2 variant severity from 2020-2023 •  SARS-CoV-2 whole-genome sequencing from 6,916 respiratory swabs was performed •  Four conserved kmer sequences associated with severity were identified •  Infections from the Delta variant had highest likelihood of severe infection •  Omicron BA.4/5 variant was more severe than BA.1 in children, vice-versa in adults Abstract We performed virus whole-genome sequencing of 6,916 upper respiratory swabs from adults and children from March 2020 through May 2023 and collected clinical metadata to assess differences in SARS-CoV-2 variant severity and symptomatology. Multivariable logistic regression showed a severity peak with Delta , which had the highest likelihood of severe infection. In children , another peak was observed with BA.4/BA.5 , which was associated with more severe infection than both prior ( BA.1 ) and later ( BQ.1, BF.7, and XBB ) Omicron variants . In cont...

Summary Background mRNA-1283 is an investigational, next-generation COVID-19 vaccine that encodes only the immunodominant regions of the SARS-CoV-2 spike protein —the receptor-binding domain (RBD) and the N-terminal domain rather than the full-length spike used in currently authorised mRNA vaccines. We evaluated the relative vaccine efficacy (rVE), immunogenicity, and safety of mRNA-1283 compared to the first-generation vaccine (mRNA-1273). Methods This randomised, observer-masked, active-controlled, phase 3 trial (NextCOVE) was conducted in individuals (aged ≥12 years) with no evidence of SARS-CoV-2 infection within 90 days of screening in the USA, the UK, and Canada. Participants were randomly assigned in a 1:1 ratio to receive one 10 μg dose of the bivalent formulation of mRNA-1283 (original plus omicron BA.4/BA.5) or 50 μg of the bivalent mRNA-1273, encoding the same variants. Randomisation was stratified by age (12–17 years, 18–64 years, and ≥65 years). Primary objectives comparin...

  Am J Respir Crit Care Med MICHELS EHA, Peters-Sengers H, de Brabander J, Schuurman AR, et al The Plasma Proteome in Community-acquired Pneumonia: Pathophysiology, Outcome and 10-Year Risk. Am J Respir Crit Care Med. 2025 Jul 2. doi: 10.1164/rccm.202502-0325. PubMed           Abstract available Ann Intern Med CROSLEY E, Martin GS In COVID-19 acute hypoxemic respiratory failure, awake prone positioning vs. supine positioning increases survival without intubation. Ann Intern Med. 2025 Jul 1. doi: 10.7326/ANNALS-25-02004. PubMed           Abstract available BMJ COOPER N, Agius S, Freeman K, Church H, et al Impact of physician assistants on quality of care: rapid review. BMJ. 2025;390:e086358. PubMed           Abstract available KIRKLAND A, Greer SL The antivaccine movement threatens health in the US and worldwide. BMJ. 2025;390:r1383. PubMed     ...

  Antiviral Res HUSSAIN S, Meijer A, Govorkova EA, Dapat C, et al Global update on the susceptibilities of influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2020-2023. Antiviral Res. 2025 Jun 24:106217. doi: 10.1016/j.antiviral.2025.106217. PubMed           Abstract available Clin Infect Dis HARUN MGD, Sumon SA, Anwar MMU, Mohona TM, et al Infection Prevention and Control Knowledge, Attitudes, and Practices of Healthcare Workers in Tertiary Care Hospitals in Bangladesh During Coronavirus Disease 2019: A Multicenter Cross-sectional Survey. Clin Infect Dis. 2025 Jun 25:ciaf246. doi: 10.1093. PubMed           Abstract available DUONG KS, Henry SS, Duong TQ SARS-CoV-2 infection increases long-term risk of pneumonia in an urban population: an observational cohort study up to 46 months post-infection. Clin Infect Dis. 2025 Jun 25:ciaf345. doi: 10.1093. PubMe...

  Am J Obstet Gynecol KOENIG LR, Raymond EG, Upadhyay UD, Frye LJ, et al Effectiveness and safety of medication abortion with vs. without screening ultrasonography or pelvic exam. Am J Obstet Gynecol. 2025 Jun 11:S0002-9378(25)00387. PubMed           Abstract available J Med Virol YIN L, He H, Zhang H, Shang Y, et al Revolution of AAV in Drug Discovery: From Delivery System to Clinical Application. J Med Virol. 2025;97:e70447. PubMed           Abstract available TANG X, Zhou Y, Sun Y, Ding T, et al Proteomics and Phosphoproteomics Characteristics of the Rhesus Macaque Lung Infected With Original SARS-CoV-2, Delta, and Omicron Variants. J Med Virol. 2025;97:e70446. PubMed           Abstract available WU F, Zhang Z, Lun Q, Hong X, et al Papain-Like Protease of SARS-CoV-2 Induces Intestinal Inflammation via the ISG15 Pathway: Identification of Natural Compound Inhibi...

Abstract Background :  The experience of the COVID-19 pandemic has differed across continents. We hypothesized that regional differences in SARS-CoV-2 immunity might explain this observation. We therefore established the WWW Consortium in Ghana , W Africa; Jamaica , W Indies ; and W London . Here, we describe the extent to which antibody immunity differs between these geographic locations.  Methods :  The WWW Consortium harmonises across the HERITAGE (Accra, Ghana), WINDFall (Kingston, Jamaica) and Legacy (London, UK) studies, establishing sharing frameworks for samples , metadata, and data; related permissions and oversight; and associated physical and cloud infrastructure. With centralised testing, we performed serological assessments across all three locations at two snapshots in 2024 (April 1st - August 18th; August 19th - December 31st) using high-throughput live virus neutralization and anti-nucleocapsid IgG, including n=763 individuals.  Findings :  We fo...

  Antiviral Res CHANG CW, Oswal N, Murugan M, Goldgirsh K, et al A novel cellular tool for screening human pan-coronavirus antivirals. Antiviral Res. 2025 Jun 10:106212. doi: 10.1016/j.antiviral.2025.106212. PubMed           Abstract available Clin Infect Dis LEE R, Kim N, Kim WB, Im KI, et al Effectiveness and safety of Autologous Virus-Specific T Cell Therapy for Persistent COVID-19 in People with Immunocompromise: A Clinical Trial Study. Clin Infect Dis. 2025 Jun 10:ciaf302. doi: 10.1093. PubMed           Abstract available SUDNIK P, Walsh EE, Branche AR, Islam M, et al Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized with RSV. Clin Infect Dis. 2025 Jun 12:ciaf310. doi: 10.1093. PubMed           Abstract available Int J Infect Dis WEE LE, Ho RWL, Lim JT, Chiew CJ, et al Long-term multi-systemic sequelae post-hospitalizat...